Volume 6.29 | Aug 5

Mesenchymal Cell News 6.29 August 5, 2014
Mesenchymal Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  MESCN on Twitter
Paclitaxel Is Incorporated by Mesenchymal Stromal Cells and Released in Exosomes that Inhibit In Vitro Tumor Growth: A New Approach for Drug Delivery
Scientists found that mesenchymal stromal cells can acquire strong anti-tumor activity after priming with paclitaxel through their capacity to uptake and then release the drug. [J Control Release] Abstract
Request Your Free Wallchart: Mesenchymal Stem Cells (A Nature Reviews Molecular Cell Biology Collaboration)
PUBLICATIONS (Ranked by impact factor of the journal)
The Bone Marrow Stromal Compartment in Multiple Myeloma Patients Retains Capability for Osteogenic Differentiation In Vitro: Defining the Stromal Defect in Myeloma
Scientists quantified the number of fibroblast colony-forming units and osteoblast colony-forming units in freshly isolated bone marrow from healthy individuals and multiple myeloma patients. [Br J Haematol] Abstract

Equine Mesenchymal Stromal Cells and Embryo-Derived Stem Cells Are Immune Privileged In Vitro
No immune response is reported following in vivo injection of allogeneic equine mesenchymal stem cells or embryo-derived stem cells into the equine tendon, which may be due to the cells’ immune privileged properties. Researchers investigated these properties to determine their potential for clinical application in other tissues. [Stem Cell Res Ther] Abstract | Full Article

Non-Pulsed Sinusoidal Electromagnetic Fields as a Noninvasive Strategy in Bone Repair: The Effect on Human Mesenchymal Stem Cell Osteogenic Differentiation
Scientists studied the effect of non-pulsed sinusoidal electromagnetic field radiation tuned at calcium-ion cyclotron frequency of 50 Hz exposure treatment for bone differentiation of human mesenchymal stem cells alone or in synergy with dexamethasone, their canonical chemical differentiation agent. [Tissue Eng Part C Methods] Abstract

Discovery and Characterization of miRNA during Cellular Senescence in Bone Marrow-Derived Human Mesenchymal Stem Cells
Investigators identified and characterized miRNAs during cellular senescence in mesenchymal stem cells (MSCs). 19 miRNAs showed upregulated expression patterns in senescent MSCs compared with young MSCs, and five miRNAs were downregulated. [Exp Gerontol] Abstract

A p38 MAPK-Mediated Alteration of COX-2/PGE2 Regulates Immunomodulatory Properties in Human Mesenchymal Stem Cell Aging
Scientists evaluated the effect of replicative senescence on the immunomodulatory ability of human mesenchymal stem cells (hMSCs) in vitro and in vivo. Late-passage hMSCs showed impaired suppressive effect on mitogen-induced mononuclear cell proliferation. [PLoS One] Full Article

Enhanced Healing of Rat Calvarial Defects with MSCs Loaded on BMP-2 Releasing Chitosan/Alginate/Hydroxyapatite Scaffolds
Investigators evaluated the effect of the chitosan/alginate/hydroxyapatite scaffold as a carrier for recombinant BMP-2 scaffold on the viability and differentiation of bone marrow mesenchymal stem cells (MSCs) by scanning electron microscopy, MTS, ALP assay, alizarin-red staining and qRT-PCR. [PLoS One] Full Article

Therapeutic Effects of Mesenchymal Stem Cell-Derived Microvesicles on Pulmonary Arterial Hypertension in Rats
Scientists investigated the therapeutic effects of mesenchymal stem cell derived microvesicles on pulmonary artery hypertension in rats. [Acta Pharmacol Sin] Abstract

Evaluation of New Bone Formation in Irradiated Areas Using Association of Mesenchymal Stem Cells and Total Fresh Bone Marrow Mixed with Calcium Phosphate Scaffold
The authors previously demonstrated the efficacy of biphasic calcium phosphate (BCP) and total fresh bone marrow (TBM) in regenerating irradiated bone defect. They studied whether adding mesenchymal stem cells to BCP + TBM mixture could improve the bone formation in irradiated bone defects. [J Mater Sci Mater Med] Abstract

Request Sample: ReLeSR™, Easy Passaging Through Selective Detachment of hPSCs
Caveats of Mesenchymal Stem Cell Therapy in Solid Organ Transplantation
The authors address the potential pitfalls for the use of mesenchymal stem cells (MSCs) as a therapeutic agent to control alloimmune effects. The aim of this review is not to discourage investigators from clinical studies, but to raise awareness of the intrinsic risks of MSC therapy. [Transpl Int] Abstract

Visit our reviews page to see a complete list of reviews in the mesenchymal cell research field.

Fraunhofer Life Science Symposium
Cynata Contracts University of Wisconsin – Madison to Advance Cymerus™ Stem Cell Product Development
Cynata Therapeutics Ltd. announced that it has signed an agreement with the University of Wisconsin – Madison to develop a novel approach for preserving cell therapy products to enhance their shelf life and convenience. [Cynata Therapeutics Ltd.] Press Release

Israel’s Ministry of Health Approves Pluristem’s Commercial-Scale 3D Cell Manufacturing Process Used at Its New Haifa Facility
Pluristem Therapeutics Inc. announced that it has completed the approval process and received final clearance from a fifth regulatory agency for its 3D cell therapy manufacturing processes in use at its new facility in Haifa. [Pluristem Therapeutics Inc.] Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW New York Stem Cell Foundation 9th Annual Translational Stem Cell Research Conference
October 22-23, 2014
New York City, United States

Visit our events page to see a complete list of events in the mesenchymal cell community.
NEW Postdoctoral Position – Biomaterials/Cartilage Regeneration (Peking University)

NEW Cell Biology Technician (University of Pittsburgh School of Medicine)

NEW Postdoctoral Fellowship – Developing Applications of Mesenchymal Stromal/Stem Cells in Hematopoietic Cell Transplantation (The Research Institute at Nationwide Children’s Hospital)

Postdoctoral Positions – Tissue Engineering and Regenerative Medicine (University of the Andes)

Technical Account Manager (GlobalStem)

Postdoctoral Fellow – Crosstalk and Interactions between Skeletal Cells and the Blood Vessels of Bone (KU Leuven)

PhD Position – Pericyte Function and Dysfunction in CNS Disease (Lund University)

Postdoctoral Position – Mesenchymal Stem Cells (University of Southern California)

Scientist – Mesenchymal Stem and Progenitor Cell Biology (STEMCELL Technologies Inc.)

Scientist – Myogenic Progenitor Cell Biology (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mesenchymal Cell News: Archives | Events | Contact Us